Ketamine Hydrochloride Injection, Solution
NDC Package 68083-504-10
Package Information
Ketamine Hydrochloride injection is indicated: • as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. This formulation utilizes a injection, solution delivery system. Marketed by Gland Pharma Limited, this product is identified by NDC 68083-504 and is authorized under FDA application ANDA216809.
Identification & Billing
- RxCUI: 238082 - ketamine 10 MG/ML Injectable Solution
- RxCUI: 238082 - ketamine (as ketamine hydrochloride) 10 MG/ML Injectable Solution
- RxCUI: 238083 - ketamine 100 MG/ML Injectable Solution
- RxCUI: 238083 - ketamine (as ketamine hydrochloride) 100 MG/ML Injectable Solution
- RxCUI: 238084 - ketamine 50 MG/ML Injectable Solution
Clinical Specifications
- Intramuscular - Administration within a muscle.
- Intravenous - Administration within or into a vein or veins.
Regulatory & Marketing
Hierarchy Structure
- 68083 - Gland Pharma Limited
- 68083-504 - Ketamine Hydrochloride
- 68083-504-10 - 10 VIAL in 1 CARTON / 20 mL in 1 VIAL
- 68083-504 - Ketamine Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68083-504-10 identifies a specific commercial package of 10 vial in 1 carton / 20 ml in 1 vial of Ketamine Hydrochloride, a human prescription drug labeled by Gland Pharma Limited. This injection, solution is formulated for intramuscular; intravenous use and contains ketamine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gland Pharma Limited on January 24, 2023. The current certification is valid through December 31, 2027.
How is this Gland Pharma Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68083050410. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.